SLC38A2 and neoplasm: Notably, similar to FLCN deficiency, SLC38A2 deficiency in DCs eliminates the anti-tumour effect of glutamine supplementation, thereby establishing this glutamine transporter and FLCN signalling as critical drivers of cDC1 function and tumour immunity.